IBDEI0KU ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9872,2)
 ;;=Hyphema^60498
 ;;^UTILITY(U,$J,358.3,9873,0)
 ;;=364.05^^44^558^51
 ;;^UTILITY(U,$J,358.3,9873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9873,1,3,0)
 ;;=3^Hypopyon
 ;;^UTILITY(U,$J,358.3,9873,1,4,0)
 ;;=4^364.05
 ;;^UTILITY(U,$J,358.3,9873,2)
 ;;=Hypopion^60720
 ;;^UTILITY(U,$J,358.3,9874,0)
 ;;=365.02^^44^558^4
 ;;^UTILITY(U,$J,358.3,9874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9874,1,3,0)
 ;;=3^Angle, Narrow
 ;;^UTILITY(U,$J,358.3,9874,1,4,0)
 ;;=4^365.02
 ;;^UTILITY(U,$J,358.3,9874,2)
 ;;=Angle, Narrow^268748
 ;;^UTILITY(U,$J,358.3,9875,0)
 ;;=372.63^^44^558^117
 ;;^UTILITY(U,$J,358.3,9875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9875,1,3,0)
 ;;=3^Symblepharon
 ;;^UTILITY(U,$J,358.3,9875,1,4,0)
 ;;=4^372.63
 ;;^UTILITY(U,$J,358.3,9875,2)
 ;;=Symblepharon^265885
 ;;^UTILITY(U,$J,358.3,9876,0)
 ;;=372.75^^44^558^27
 ;;^UTILITY(U,$J,358.3,9876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9876,1,3,0)
 ;;=3^Cysts, Conjunctival
 ;;^UTILITY(U,$J,358.3,9876,1,4,0)
 ;;=4^372.75
 ;;^UTILITY(U,$J,358.3,9876,2)
 ;;=Cysts, Conjunctival^269049
 ;;^UTILITY(U,$J,358.3,9877,0)
 ;;=364.81^^44^558^43
 ;;^UTILITY(U,$J,358.3,9877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9877,1,3,0)
 ;;=3^Floppy Iris Syndrome
 ;;^UTILITY(U,$J,358.3,9877,1,4,0)
 ;;=4^364.81
 ;;^UTILITY(U,$J,358.3,9877,2)
 ;;=^335254
 ;;^UTILITY(U,$J,358.3,9878,0)
 ;;=006.9^^44^558^2
 ;;^UTILITY(U,$J,358.3,9878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9878,1,3,0)
 ;;=3^Amebiasis
 ;;^UTILITY(U,$J,358.3,9878,1,4,0)
 ;;=4^006.9
 ;;^UTILITY(U,$J,358.3,9878,2)
 ;;=^5818
 ;;^UTILITY(U,$J,358.3,9879,0)
 ;;=190.8^^44^558^60
 ;;^UTILITY(U,$J,358.3,9879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9879,1,3,0)
 ;;=3^Iris Melanoma,Contiguous Site
 ;;^UTILITY(U,$J,358.3,9879,1,4,0)
 ;;=4^190.8
 ;;^UTILITY(U,$J,358.3,9879,2)
 ;;=^267278
 ;;^UTILITY(U,$J,358.3,9880,0)
 ;;=224.1^^44^558^93
 ;;^UTILITY(U,$J,358.3,9880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9880,1,3,0)
 ;;=3^Orbit Neoplasm,Benign
 ;;^UTILITY(U,$J,358.3,9880,1,4,0)
 ;;=4^224.1
 ;;^UTILITY(U,$J,358.3,9880,2)
 ;;=^267671
 ;;^UTILITY(U,$J,358.3,9881,0)
 ;;=360.33^^44^558^52
 ;;^UTILITY(U,$J,358.3,9881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9881,1,3,0)
 ;;=3^Hypotony,Assoc w/ Ocular D/O
 ;;^UTILITY(U,$J,358.3,9881,1,4,0)
 ;;=4^360.33
 ;;^UTILITY(U,$J,358.3,9881,2)
 ;;=^268560
 ;;^UTILITY(U,$J,358.3,9882,0)
 ;;=224.8^^44^558^86
 ;;^UTILITY(U,$J,358.3,9882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9882,1,3,0)
 ;;=3^Neopl Eye Bgn,Oth Iris Nevus
 ;;^UTILITY(U,$J,358.3,9882,1,4,0)
 ;;=4^224.8
 ;;^UTILITY(U,$J,358.3,9882,2)
 ;;=^267678
 ;;^UTILITY(U,$J,358.3,9883,0)
 ;;=364.01^^44^558^103
 ;;^UTILITY(U,$J,358.3,9883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9883,1,3,0)
 ;;=3^Prim Iridocyclitis
 ;;^UTILITY(U,$J,358.3,9883,1,4,0)
 ;;=4^364.01
 ;;^UTILITY(U,$J,358.3,9883,2)
 ;;=^268704
 ;;^UTILITY(U,$J,358.3,9884,0)
 ;;=364.04^^44^558^53
 ;;^UTILITY(U,$J,358.3,9884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9884,1,3,0)
 ;;=3^Iridociclyties 2ary,Non Infectious
 ;;^UTILITY(U,$J,358.3,9884,1,4,0)
 ;;=4^364.04
 ;;^UTILITY(U,$J,358.3,9884,2)
 ;;=^268710
 ;;^UTILITY(U,$J,358.3,9885,0)
 ;;=364.21^^44^558^46
 ;;^UTILITY(U,$J,358.3,9885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9885,1,3,0)
 ;;=3^Fuch's Hetero Cyclitis
 ;;^UTILITY(U,$J,358.3,9885,1,4,0)
 ;;=4^364.21
 ;;^UTILITY(U,$J,358.3,9885,2)
 ;;=^48468
 ;;^UTILITY(U,$J,358.3,9886,0)
 ;;=364.23^^44^558^81
 ;;^UTILITY(U,$J,358.3,9886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9886,1,3,0)
 ;;=3^Lens-Induced Iridocyclitis
 ;;
 ;;$END ROU IBDEI0KU
